Market Research Report
Biosimilars: Global Market, Trends and Competitor Analysis
|Published by||Kalorama Information||Product code||96359|
|Published||Content info||214 Pages
Delivery time: 1-2 business days
|Biosimilars: Global Market, Trends and Competitor Analysis|
|Published: November 14, 2017||Content info: 214 Pages||
Worldwide interest in biosimilars is gaining momentum. These close models of significant and profitable biopharmaceuticals are expected to have a dramatic market impact. Some of the biggest-selling biological drugs developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, have lost patent protection.
This Kalorama Information report, Biosimilars: Global Market, Trends, and Competitor Analysis, addresses these points and more. The report is a detailed analysis both of the market for biosimilars and for the market effects on pharmaceutical markets. Kalorama Information last visited this topic in 2013, but since that time there has been increasing worldwide involvement in the development of the biosimilar arena.
The global market for biosimilar products has grown, adding to the growing strategies of cost savings and improved health outcomes. Despite the benefits, both economical and to patient health, the market was initially slow to develop and has thus far only reached a fraction of its potential. Biosimilars: Global Market, Trends, and Competitor Analysis provides the complete world and regional picture of the follow-on biologics market, now one of the hottest segments in the pharmaceutical industry, including information on the following market segments:
Insulin, blood products and monoclonal antibodies are expected to show the most potential for generic equivalent products. Generic versions are available in several world markets for epoetin alfa, rituximab, insulin, and other products. As we move through the forecast period, biosimilars in cancer treatment are expected to show favorable results. Although revenues for biosimilars remain small due to the regulatory restrictions in most lucrative markets, such as the United States, there are a number of products, which entered recently or will enter the market in the coming years, further expanding revenues for the biosimilar market. The report looks at the market by application, including the following:
The world market for biosimilars has historically been fueled primarily by the demand for bioequivalent versions of blood products erythropoietin and G-CSF. A focus for biosimilar production in the United States and key markets in Europe is hGH. Another area showing great promise is the monoclonal antibody segment, which includes several autoimmune and oncology products. Biosimilars: Global Market, Trends, and Competitor Analysis breaks down the biosimilars market by product type, including the following segments:
The issues and trends surrounding the prescription biosimilar pharmaceutical market are staggering and in some cases seemingly insurmountable. But as the pharmaceutical industry has experienced in the past, the generics industry is tough, resilient and determined, managing to overcome obstacles and prevail. The report discusses many of the market issues that will need to be addressed moving forward, including:
Biosimilars: Global Market, Trends, and Competitor Analysis provides a complete competitor analysis for 2017, by percentage of global market share. There is a smaller group of companies engaging in the development and commercialization of biosimilar products than is normally seen in the mainstream generic industry. This is due to significant barriers to entry into the market, though current trends in biotechnology are bringing new opportunities for the biosimilars industries in the future. The companies participating in this unique market, which require a combination of biopharmaceutical knowledge and manufacturing expertise, are profiled in the report, including:
The report draws six main market conclusions that involve patent protection, pricing, market participants, emerging markets, evolving market strategies and education.